Журнал «Почки» Том 11, №4, 2022
Вернуться к номеру
Коротке резюме Настанови з клінічної практики щодо лікування цукрового діабету в пацієнтів із хронічною хворобою нирок (KDIGO) 2022 р.: оновлення на підставі нових, оперативно отриманих доказових даних
Авторы: Peter Rossing (1, 2), M. Luiza Caramori (3), Juliana C.N. Chan (4, 5) et al.
(1) — Копенгагенський діабетичний центр ім. Н. Стено (Steno Diabetes Center Copenhagen), Копенгаген, Данія
(2) — Копенгагенський університет (University of Copenhagen), Копенгаген, Данія
(3) — Кафедра діабету, ендокринології й обміну речовин, Університет Міннесоти (University of Minnesota), Міннеаполіс, Міннесота, США
(4) — Кафедра медицини та лікарських засобів, Університет діабету й ожиріння в Гонконзі (Hong Kong Institute of Diabetes and Obesity), Гонконг, Китай
(5) — Інститут медичних наук Лі Ка Шин, Китайський університет у Гонконзі (Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong), Гонконг, Китай
Рубрики: Нефрология
Разделы: Официальная информация
Версия для печати
Повний текст Настанови з клінічної практики щодо лікування цукрового діабету в пацієнтів із хронічною хворобою нирок (KDIGO) 2022 р. опубліковано в науковому журналі Kidney International, том 102, випуск 5S, за листопад 2022 р., який доступний онлайн за посиланням www.kidneyinternational.org.
Настанова з клінічної практики «Захворювання нирок: ініціатива з покращення глобальних результатів лікування цукрового діабету в пацієнтів із захворюваннями нирок» 2022 року (The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD)) є цілеспрямованим оновленням попередньої настанови KDIGO із цього питання 2020 року. Ця настанова спрямована на широку аудиторію клініцистів, які ...
Для ознакомления с полным содержанием статьи необходимо оформить подписку на журнал.
Список литературы
1. Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Ma–nagement in Chronic Kidney Disease. Kidney Int. 2020. 98. S1-S115.
2. Guyatt G.H., Oxman A.D., Schunemann H.J. et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J. Clin. Epidemiol. 2011. 64. 380-382.
3. Chan J.C., So W.Y., Yeung C.Y. et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. Diabetes Care. 2009. 32. 977-982.
4. Chan J.C.N., Thewjitcharoen Y., Nguyen T.K. et al. Effect of a web-based management guide on risk factors in patients with type 2 diabetes and diabetic kidney disease: a JADE randomized clinical trial. JAMA Netw. Open. 2022. 5. e223862.
5. Gaede P., Vedel P., Parving H. et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999. 353. 617-622.
6. Ueki K., Sasako T., Okazaki Y. et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017. 5. 951-964.
7. de Boer I.H., Khunti K., Sadusky T. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. Published online October 3, 2022. https://doi. org/10.2337/dci22-0027.
8. Anker S.D., Butler J., Filippatos G. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 2021. 385. 1451-1461.
9. Bhatt D.L., Szarek M., Pitt B. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med. 2021. 384. 129-139.
10. Bhatt D.L., Szarek M., Steg P.G., et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 2021. 384. 117-128.
11. Cannon C.P., Pratley R., Dagogo-Jack S. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N. Engl. J. Med. 2020. 383. 1425-1435.
12. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 2020. 383. 1436-1446.
13. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019. 381. 1995-2008.
14. Packer M., Anker S.D., Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 2020. 383. 1413-1424.
15. EMPA-Kidney Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol. Dial. Transplant. 2022. 37. 1317-1329.
16. Bakris G., Oshima M., Mahaffey K.W. et al. Effects of canagliflozin in patients with baseline eGFR < 30 ml/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial. Clin. J. Am. Soc. Nephrol. 2020. 15. 1705-1714.
17. Chertow G.M., Vart P., Jongs N. et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J. Am. Soc. Nephrol. 2021. 32. 2352-2361.
18. Persson F., Rossing P., Vart P. et al. Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial. Diabetes Care. 2021. 44. 1894-1897.
19. Zoungas S., de Boer I.H. SGLT2 inhibitors in diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2021. 16. 631-633.
20. Gerstein H.C., Sattar N., Rosenstock J. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 2021. 385. 896-907.
21. Alicic R.Z., Patakoti R., Tuttle K.R. Direct and indirect effects of obesity on the kidney. Adv. Chronic Kidney Dis. 2013. 20. 121-127.
22. Bays H., Pi-Sunyer X., Hemmingsson J.U. et al. Liraglutide 3.0 mg for weight management: weight-loss dependent and independenteffects. Curr. Med. Res. Opin. 2017. 33. 225-229.
23. Shah P.P., Brady T.M., Meyers K.E.C. et al. Association of obesity with cardiovascular risk factors and kidney disease outcomes in primary proteinuric glomerulopathies. Nephron. 2021. 145. 245-255.
24. Tuttle K.R., Lakshmanan M.C., Rayner B. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018. 6. 605-617.
25. Bakris G.L., Agarwal R., Anker S.D. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 2020. 383. 2219-2229.
26. Pitt B., Filippatos G., Agarwal R. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 2021. 385. 2252-2263.
27. Rossing P., Anker S.D., Filippatos G. et al., FIDELIO-DKD and FIGARO-DKD Investigators. Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: The FIDELITY Analysis. Diabetes Care. Published online August 15, 2022. https://doi.org/10.2337/dc22-0294.
28. Ito S., Kashihara N., Shikata K. et al. Esaxerenone –(CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin. J. Am. Soc. Nephrol. 2020. 15. 1715-1727.
29. Ito S., Shikata K., Nangaku M. et al. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase ii trial. Clin. J. Am. Soc. Nephrol. 2019. 14. 1161-1172.
30. Neuen B.L., Oshima M., Agarwal R. et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022. 145. 1460-1470.
31. Neuen B.L., Oshima M., Perkovic V. et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur. Heart J. 2021. 42. 4891-4901.
32. Pitt B., Pfeffer M.A., Assmann S.F. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 2014. 370. 1383-1392.
33. Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 1999. 341. 709-717.
34. American Diabetes Association Professional Practice Committee, Draznin B., Aroda V.R., Bakris G. et al. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes — 2022. Diabetes Care. 2022. 45 (Suppl. 1). S144-S174.
35. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016. 37. 2129-2200.
36. Yancy C.W., Jessup M., Bozkurt B. et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the ma–nagement of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017. 136. e137-e161.
37. Kliger A.S., Brosius F.C. Diabetic Kidney Disease Task Force of the American Society of Nephrology. Preserving kidneyfunction instead of replacing it. Clin. J. Am. Soc. Nephrol. 2020. 15. 129-131.
38. Chan J.C.N., Lim L.L., Wareham N.J. et al. The Lancet Commission on Diabetes: using data to transform diabetes care and patient lives. Lancet. 2021. 396. 2019-2082.
39. Brosius F.C., Cherney D., Gee P.O. et al. Transforming the care of patients with diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 2021. 16. 1590-1600.
40. Tuttle K.R., Wong L., Peter W. et al., Diabetic Kidney Disease Collaborative Task Force. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. disease. Clin. J. Am. Soc. Nephrol. 2022. 17. 1092-1103.
41. Abegaz T.M., Diaby V., Sherbeny F. et al. Cost effectiveness of dapagliflozin added to standard of care for the management of diabetic nephropathy in the USA. Clin. Drug Investig. 2022. 42. 501-511.
42. Igarashi A., Maruyama-Sakurai K., Kubota A. et al. Cost-effectiveness analysis of initiating type 2 diabetes therapy with a sodium-glucose cotransporter 2 inhibitor versus conventional therapy in Japan. Diabetes Ther. 2022. 13. 1367-1381.
43. Reifsnider O.S., Kansal A.R., Wanner C. et al. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial. Am. J. Kidney Dis. 2022. 79. 796-806.
44. Kelsey M.D., Nelson A.J., Green J.B. et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison. J. Am. Coll. Cardiol. 2022. 79. 1849-1857.